Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease

NICE technology appraisal guidance [TA20] Published date:

NICE has recommended that riluzole should be available for the treatment of individuals with MND in accordance with its licensed indications.

Treatment with riluzole should only be started by a neurological specialist who is experienced in the management of MND. Routine supervision of therapy may be managed by general practitioners, but this should be under an agreement known as a shared care arrangement with the specialist.

Get involved